orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation
orkambi 200 mg 125 mg film coated tabltes
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
circadin
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
kalydeco 50 mg granules
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 50 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.
kalydeco 75 mg granules
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 75 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.
rye pharmaceuticals burnaid burn gel spray
pan-malayan pharmaceuticals pte ltd - physical medicine - (1)for first aid use on minor burns, scalds and sunburn. (2)offers cooling soothing relief from burns, scalds and sunburn.
university medical pharmaceuticals hand sanitizer- alcohol liquid
university medical pharmaceuticals corp. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic ■ hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available.